Pharmacoeconomic evaluation of high-dose chemotherapy and peripheral blood stem cell support in high-risk or poor-prognosis malignancies

Journal of Cancer Research and Clinical Oncology

Volumn 124, Issue 5, 1998, Pages 288-290

  Kath, R ^a   Hartmann, M ^a   Hoffken K ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

High dose chemotherapy; Peripheral blood stem cell support; Pharmacoeconomics

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MEGADOSE; HIGH RISK POPULATION; HUMAN; MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; DRUG COSTS; GERMANY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; NEOPLASMS; NEUTROPENIA; PROGNOSIS;

EID: 0031779045     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050170     Document Type: Article

References (18)

1. Bennett CL, et al (1995) Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 13:969-973
2. Faucher C, et al (1994) Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 14:895-901
3. Fields K, Perkins JP, Hiemenz JW, et al (1993) Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients. Surg Oncol 2:87-95
4. Gilbert CJ (1996) Peripheral blood progenitor cell transplantation for breast cancer: pharmacoeconomic considerations. Pharmacotherapy 16:101-108
5. Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Räth U, Siegert W, Sonntag R, Hartenstein R, Clemm C, Wilke H, Poliwoda H (1991) Cisplatin/etoposide/ifosfamide stepwise dose escalation with far-advanced testicular carcinoma. J Cancer Res Clin Oncol 117 [Suppl IV]:189-202
6. Hartmann O, et al (1997) Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 126:600-760
7. Hillner BE, Smith TJ, Desch CE (1992) Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055-2061
8. Juttner CA, To LB, Roberts MM (1992) Comparison of haematological recovery, toxicity and supportive care of autologous PBSC, autologous BM and allogenic BM transplants. Proceedings of the second international symposium of PBSC autografts. Int J Cell Cloning 10:1-206
9. Klaassen U, et al (1994) Studienprotokoll: Randomisierte multizentrische Therapiestudie zur adjuvanten Therapie des Mammakarzinoms Adjuvante Hochdosis-Chemotherapie mit peripherer Blutstammzellretransfusion im Vergleich mit dosisintensivierter Standardtherapie bei Hochrisikopatientinnen mit Mammakarzinom im Stadium III.
10. Lawless GD (1995) Cost-effectiveness of autologous bone marrow transplantation. Am J Health Syst Pharm 52 [Suppl 4]:11-14
11. Lobo PJ, et al. (1991) Acute myeloblastic leukaemia a model for assessing value for money for new treatment programmes. B. Med J 302:323-326
12. McQuaker IG, et al. (1997) Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 15:451-457
13. Pfreundschuh M, Rüffer U, Hasenclever D, Loeffler M, Koch P, Ehninger G, Kirchner H, Lathan B, Schmitz N, Diehl V (1993) GM-CSF increases the maximum tolerated dose of etoposide in the dexa-beam regimen for refractory Hodgkin's desease (HD): a randomized placebo-controlled double-blind multicenter trial of the German Hodgkin's study group (GHSG). Proc Am Soc Clin Obcol Annu Meet 12
14. Smith TJ, Hillner BE (1993) The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 11:771-776
15. Studiengruppe Plasmocytom (1994) Studienprtotokoll: Sequentielle Tandem-Hochdosistherapie beim multiplen Myelom mit Unterstützung der Knochenmarksregeneration durch Retransfusion von ins Blut mobilisierten hämatopoetischen Vorläuferzellen: Wert einer ex vivo-Anreicherung der hämatopoetischen Vorläuferzellen. Ulm
16. Viens-Bitker C, Frey-Lemonnier E, Blum-Boisgard C (1989) Cost of allogenic bone marrow transplantation in four diseases. Health Policy Monogr 12:309-317
17. Welch HG, Larson EB (1989) Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 321:807-812
18. Westerman IL, Bennett CL (1996) A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation. Stem Cells 14:312-319